Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK

NCT00182650 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00182650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00182650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2004
Completion date
March 31, 2008
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma